These model systems indicate that PCa cells possess phenotypical plasticity to adapt to ARPI treatments by using various intracellular mechanisms to switch off the ligand-dependent AR signalling and switch on the ligand-independent AR signalling, and bypass AR through other oncogenic kinase pathways (Figure 1). The gene discussed is AR; the disease is posterior cortical atrophy.